Artivion NASDAQ:AORT Executive Vice President, Chief Operating Officer, Chief Financial Officer and Treasurer Lance A. Berry sold 6,316 shares of Artivion common stock on March 3, 2026. The reported transaction was executed at a unit price of $37.7756, producing proceeds of $238,590.
The share sale immediately followed a grant the previous day. On March 2, 2026, Berry received 40,874 shares of Artivion common stock that were recorded with a value of $0. Those shares represent a portion of performance stock units originally granted on February 28, 2025. The remaining portion of that award is scheduled to vest in two future tranches, in 2027 and 2028.
According to the disclosure, the 6,316 shares sold were used to satisfy tax obligations tied to the vesting of the performance stock units. After completing the sale, Berry is listed as directly owning 210,827 shares of Artivion common stock.
Market commentary included with the filings notes an InvestingPro analysis that currently considers the stock overvalued relative to its Fair Value, highlighting a related InvestingPro Tip that the company is "trading at a high earnings multiple." The disclosure indicates there are 14 additional ProTips and a full Pro Research Report available for AORT for investors who seek more detailed analysis.
These insider transactions coincide with recent company operating results for the fourth quarter of 2025. Artivion reported adjusted earnings per share of $0.17 for Q4 2025, outpacing the projected $0.06 estimate. Adjusted revenues were $118.3 million, representing 18.5% year-over-year growth on a constant currency basis after accounting for a one-time $2.3 million payment to the Italian government.
The reported revenue figure exceeded both Canaccord Genuity’s internal estimate of $115.6 million and the consensus forecast of $116.5 million. Despite the stronger-than-expected earnings performance, the company slightly missed revenue forecasts overall. The company’s strategic growth initiatives were cited positively in the reporting.
Separately, Canaccord Genuity revised its price target for Artivion to $48 from $51 while maintaining a Buy rating. The firm said the adjustment was driven by compressed multiples among comparable groups in the wake of a recent stock market sell-off. Collectively, the insider sale, the quarterly results and the analyst update provide current indicators of company performance and market commentary around Artivion’s outlook.
Note: If information in any section appears limited, the article reflects only the disclosures and commentary provided in the filings and analyst notes.